Remove 2025 Remove Patients Remove Side effects
article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. It has to persuade patients to sign up for some heinous side effects. When patients stop taking Wegovy, their appetite returns within weeks, and they pack on weight. Its share price has risen 26 percent in the past year.

article thumbnail

UK agency pilots biobank to study links between genetics and drug side effects

Pharmaceutical Technology

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. Side effects due to drugs are responsible for one in every 16 hospital admissions in the UK, based on the announcement.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves first Stelara biosimilar, Wezlana

European Pharmaceutical Review

This evidence included comparisons of the products on an analytical level using chemical and biological tests and assays that confirmed similarity in the structural and functional features of Wezlana and Stelara, as well as comparative human pharmacokinetic data, clinical immunogenicity data and other clinical safety and effectiveness data.

article thumbnail

Innovating allergy drug delivery with a needle-free alternative

European Pharmaceutical Review

Additionally, EURneffy could alleviate the risk of accidental needle-related side effects (such as injection into the blood vessel and hand) 3 and it has the attributes of being smaller in size, has better temperature sensitivity, and is less complex to use compared to needle-based injectors. Motohiro E, Kento T, Kyohei T , et al.

article thumbnail

Inside the European mass shift to data-driven health solutions

Pharmaceutical Technology

The medicines regulators in Europe have a strategy for 2025 where the second pillar is data and digitalisation, so we are trying to transform medicines regulation to be data-driven,” says Peter Arlett, Head of Data Analytics and Methods Task Force at EMA. intervention) was the “cause” of an effect. Adoption of EHR data systems.

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

How can we help ensure patients continue to take their medications as prescribed? The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue. billion in 2025. But it is not a simple answer. from 2021 and reach $4.2

article thumbnail

Developing the EU’s first intestinal microbiota-based biologic

European Pharmaceutical Review

The study included 92 adult patients with confirmed CDI. After treatment, patients were followed up at intervals of 72 hours, three weeks, eight weeks, three months and six months. Safety and quality of life of the patients participating in the study were also assessed. percent of those treated with fidaxomicin.

Safety 111